Crescent Capital BDC, Inc. CCAP 深 滬
已收盤 08-07 16:00:00 美东时间
11.77
0.000
0.00%
華盛通- 最 高11.96
- 今 開11.75
- 成交量 30.43万股
- 最 低 11.7323
- 昨 收 11.77
- 總市值 4.34亿
- 52周最高 14.405
- 市盈率 靜 12.63
- 換手率 0.83%
- 52周最低 10.55
- 委 比 40.54%
- 總股本 3684.60万
- 歷史最高 17.57
- 量 比 1.62
- 振 幅 1.93%
- 歷史最低 -5.38
- 每 手 1
- 風險率 1.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its Second Quarter Ended June 30, 2026 Financial Results
Crescent Capital BDC, Inc. (NASDAQ: CCAP) announced it will release its second-quarter 2026 financial results on August 10, 2026, after market close. A webcast/conference call to discuss the results will be held on August 11, 2026, at 12:00 p.m. Eastern Time. Participants can join via the Investor Relations section of crescentbdc.com or by dialing (833) 461-5787 with Conference ID 675449280. A replay will be available on the website. Crescent BDC...
07-24 11:00
Alpha Buying: Wall Street Gave Up. Management Didn't.
One of my favorite investing stories comes from a 1978 John Train article about a Texas rice farmer and hog raiser named Mr. Womack. The story begins with an investor who spent years trying every stock market strategy he could find. He studied charts. He followed the experts. He traded in and out of...
06-18 23:40
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
Keefe, Bruyette & Woods Maintains Outperform on Crescent Capital BDC, Lowers Price Target to $13
Keefe, Bruyette & Woods analyst Paul Johnson maintains Crescent Capital BDC (NASDAQ:CCAP) with a Outperform and lowers the price target from $15 to $13.
06-16 23:36
The High-Yield Stocks the Smart Money Is Buying Right Now
Smart credit team Ares Mgmt bought discounted BDCs aggressively in Q1 2026. They're not guessing but expressing conviction in 17 positions.
05-25 01:33
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Crescent Capital BDC Balances Fee Cuts And Credit Strain
Crescent Capital Bdc, Inc. (($CCAP)) has held its Q1 earnings call. Read on for...
05-15 08:22
Crescent Capital BDC Q1 Adj. EPS $0.42, Inline, Sales $37.912M Miss $39.459M Estimate
Crescent Capital BDC (NASDAQ:CCAP) reported quarterly earnings of $0.42 per share which met the analyst consensus estimate. This is a 6.67 percent decrease over earnings of $0.45 per share from the same period last year.
05-14 05:43
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
